International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 500-503 , May 2010

Daily serum piperacillin monitoring is advisable in critically ill patients

  • Nicolas Blondiaux

      Affiliations

    • Pôle de Microbiologie, Centre de Biologie-Pathologie, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 3 20 44 54 80; fax: +33 3 20 44 48 95.
    • ,
  • Frédéric Wallet

      Affiliations

    • Pôle de Microbiologie, Centre de Biologie-Pathologie, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • ,
  • Raphaël Favory

      Affiliations

    • Service de Réanimation Médicale, Hôpital A. Calmette, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • ,
  • Thierry Onimus

      Affiliations

    • Service de Réanimation Médicale, Hôpital A. Calmette, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • ,
  • Saad Nseir

      Affiliations

    • Service de Réanimation Médicale, Hôpital A. Calmette, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • ,
  • René J. Courcol

      Affiliations

    • Pôle de Microbiologie, Centre de Biologie-Pathologie, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • ,
  • Alain Durocher

      Affiliations

    • Service de Réanimation Médicale, Hôpital A. Calmette, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France
    • ,
  • Micheline Roussel-Delvallez

      Affiliations

    • Pôle de Microbiologie, Centre de Biologie-Pathologie, Centre Hospitalier Régional Universitaire (CHRU) de Lille, Boulevard du Pr. J. Leclercq, F-59037 Lille, France

Received 16 October 2009 ,Accepted 7 January 2010.

References 

  1. Craig WA, Ebert SC. Continuous infusion of β-lactam antibiotics. Antimicrob Agents Chemother. 1992;36:2577–2583
  2. MacGowan AP, Bowker KE. Pharmacodynamics of antimicrobial agents and rationale for their dosing. J Chemother. 1997;9(Suppl. 1):64–73
  3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–10
  4. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2005;5:581–589
  5. Roberts JA, Paratz J, Paratz E, Krueger WA, Lipman J. Continuous infusion of β-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents. 2007;30:11–18
  6. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet. 2005;44:1009–1034
  7. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med. 2004;30:2145–2156
  8. Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD. Pharmacokinetics of piperacillin–tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents. 2005;25:62–67
  9. Rafati MR, Rouini MR, Mojtahedzadeh M, Najafi A, Tavakoli H, Gholami K, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents. 2006;28:122–127
  10. Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. The clinical and economic benefits of administering piperacillin–tazobactam by continuous infusion. Intensive Crit Care Nurs. 2005;21:87–93
  11. Rudrik JT, Bawdon RE. Determination of penicillinase-resistant penicillins in serum using high pressure liquid chromatography. J Liq Chromatogr. 1981;4:1525–1545
  12. Gould IM, Ansari A, Harvey G, Douglas JG, Smith CC, Reid TM. Piperacillin/tazobactam in the treatment of serious acute soft tissue infection. Drugs Exp Clin Res. 1991;17:187–190
  13. Bourget P, Lesne-Hulin A, Le Reveille R, Le Bever H, Carsin H. Clinical pharmacokinetics of piperacillin–tazobactam combination in patients with major burns and signs of infection. Antimicrob Agents Chemother. 1996;40:139–145
  14. Drlica K, Zhao X. Mutant selection window hypothesis updated. Clin Infect Dis. 2007;44:681–688
  15. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother. 1994;38:931–936

PII: S0924-8579(10)00063-4

doi: 10.1016/j.ijantimicag.2010.01.018

International Journal of Antimicrobial Agents
Volume 35, Issue 5 , Pages 500-503 , May 2010

Article Tools

* Image Usage & Resolution